Annexon Inc (ANNX)
Annexon Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing treatments for inflammatory-related diseases. Its pipeline includes Tanruprubart, an investigational full-length monoclonal antibody being studied in Phase 3 for Guillain-Barré syndrome, with prior clinical work in Huntington’s disease and amyotrophic lateral sclerosis. The company is also advancing ANX007, a Fab candidate in Phase 3 development for geographic atrophy, along with ANX1502, an oral small-molecule inhibitor in Phase 1 studies for autoimmune indications, and ANX009, a C1q-blocking Fab in Phase 1 trials for lupus nephritis. Annexon was incorporated in 2011 and is headquartered in Brisbane, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ANNX
|
$5.37
|
-1.8% Downside
|
Fair
|
$13.56
|
148.0% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
-4.5x
|
4.4x
|
—
|
912.6 M
|
699.9 M
|
2.7%
|
79.0%
|
2.6
|
—
|
92.3%
|
